DBV Technologies Shares Dip Mid-Day After Soaring Nearly 40% Yesterday
DBV Technologies experienced a significant rise of 30% on Wednesday, December 17, following the announcement of positive results from the phase 3 VITESSE clinical trial, leading to substantial trading activity. However, on Thursday, December 18, at mid-day, the stock took a slight downturn, decreasing by 5.71% to 3.47 euros from 3.68 euros the previous day.
Current Stock Performance and Technical Support
With 1.03% of the capital traded by mid-session, trading volumes remain strong though lower than the 3.79% observed the day before. Over the past seven days, the stock still shows an impressive gain of 4.68%, with increases reaching 115.8% over three months and 480.3% over a year, compared to a 10.57% rise in the CAC 40 over twelve months. The monthly volatility stands at 33.11%, typical for a biotechnological stock where fluctuations can be sharp based on clinical or regulatory announcements. The stock is now well above its moving averages, with a 50-day moving average at 2.63 euros and a 200-day moving average at 1.84 euros, confirming a strong underlying bullish trend. The technical support is at 2.26 euros, providing a comfortable safety cushion, while the resistance at 3.68 euros, breached on Tuesday during the surge, now acts as a new reference threshold. With a beta of 0.40, DBV Technologies shows moderate sensitivity to general market movements, partly explaining its outperformance compared to the Paris index.
Technical Indicators and Market Sentiment
Technically, the Relative Strength Index (RSI) reaches 74, indicating a pronounced overbought zone where buying pressures dominate significantly. This level reflects a very strong bullish momentum, fueled by favorable clinical news, but also suggests a risk of short-term correction if profit-taking intensifies. The MACD, a momentum indicator, displays a clearly bullish setup with a line at 0.24 and a signal at 0.13, generating a positive histogram of 0.11. This divergence between the line and the signal confirms that buying flows are progressively strengthening, reflecting an active accumulation dynamic despite the mid-day retreat. The Average True Range (ATR) at 0.18 euro indicates high intra-day volatility, while the Chaikin Money Flow (CMF) at -0.27 points to capital outflows, consistent with the profit-taking observed this Thursday.
Clinical Trial Success and Analyst Upgrades
The VITESSE trial achieved its primary endpoint with a significant margin, showing a responder rate that was 31.8 percentage points higher than the placebo, far exceeding the FDA's required threshold of 15%. This announcement led several analysts to revise their price targets upwards as early as Wednesday: Guggenheim raised its target from 35 to 51 dollars while maintaining a buy recommendation, Cantor Fitzgerald increased its target from 42 to 48 dollars with an overweight recommendation, and Kempen also raised its target from 6.50 to 11 euros while maintaining a buy advice. These adjustments reflect a renewed confidence in the commercial prospects of the Viaskin Peanut patch after several regulatory setbacks since 2020. The FDA has granted Breakthrough Therapy designation to the VIASKIN Peanut patch, and DBV plans to submit a Biologics License Application to the FDA in the first half of 2026. After 12 months, about 47% of patients in the Viaskin group met the criteria, compared to 15% in the placebo group, with a favorable safety profile. There were no serious adverse events related to the treatment, while the rate of anaphylaxis remained very low at 0.5%. The patch represents a non-invasive alternative to current oral treatments, with significant commercialization potential if regulatory approval is obtained.
